Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTX NASDAQ:GDTC NASDAQ:MGX NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.54-1.9%$1.69$1.28▼$9.50$52.80M1.759,218 shs58,590 shsGDTCCytoMed Therapeutics$1.14+6.5%$1.04$0.68▼$3.68$12.66M-0.0532,356 shs3,372 shsMGXMetagenomi$1.20-4.0%$1.37$1.20▼$3.95$47.06M0.64162,122 shs61,956 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$52.53M-0.1225,310 shs12,327 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics-1.91%+2.67%-17.20%-49.67%-68.05%GDTCCytoMed Therapeutics+5.65%-11.63%+50.99%+7.55%-46.23%MGXMetagenomi-4.00%-6.25%-13.04%-17.81%-19.46%XLOXilio Therapeutics+4.01%+7.92%+7.09%+16.09%-14.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.54-1.9%$1.69$1.28▼$9.50$52.80M1.759,218 shs58,590 shsGDTCCytoMed Therapeutics$1.14+6.5%$1.04$0.68▼$3.68$12.66M-0.0532,356 shs3,372 shsMGXMetagenomi$1.20-4.0%$1.37$1.20▼$3.95$47.06M0.64162,122 shs61,956 shsXLOXilio Therapeutics$8.31+4.0%$8.23$6.47▼$12.74$52.53M-0.1225,310 shs12,327 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics-1.91%+2.67%-17.20%-49.67%-68.05%GDTCCytoMed Therapeutics+5.65%-11.63%+50.99%+7.55%-46.23%MGXMetagenomi-4.00%-6.25%-13.04%-17.81%-19.46%XLOXilio Therapeutics+4.01%+7.92%+7.09%+16.09%-14.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 2.00Hold$12.00679.22% UpsideGDTCCytoMed Therapeutics 1.00SellN/AN/AMGXMetagenomi 2.80Moderate Buy$9.00650.00% UpsideXLOXilio Therapeutics 2.50Moderate Buy$28.00236.94% UpsideCurrent Analyst Ratings BreakdownLatest GDTC, DWTX, XLO, and MGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/12/2026MGXMetagenomi Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.005/8/2026XLOXilio Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026DWTXDogwood Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026GDTCCytoMed Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A$2.33 per shareN/AGDTCCytoMed Therapeutics$250K53.94N/AN/A$0.45 per share2.53MGXMetagenomi$25.21M1.79N/AN/A$4.22 per share0.28XLOXilio Therapeutics$43.77M1.25N/AN/A$7.31 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$34.26M-$10.60N/AN/AN/AN/A-108.57%-30.28%8/12/2026 (Estimated)GDTCCytoMed Therapeutics-$3.10MN/AN/AN/AN/AN/AN/AN/AN/AMGXMetagenomi-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$3.55N/AN/AN/A-58.52%-151.42%-27.61%8/13/2026 (Estimated)Latest GDTC, DWTX, XLO, and MGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026DWTXDogwood Therapeutics-$0.22-$0.15+$0.07-$0.15N/AN/A5/12/2026Q1 2026XLOXilio Therapeutics-$0.66-$0.58+$0.08-$0.58$8.52 million$12.65 million5/11/2026Q1 2026MGXMetagenomi-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million3/31/2026H2 2025GDTCCytoMed TherapeuticsN/A-$0.0550N/A-$0.0550N/A$0.06 million3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 million3/18/2026Q4 2025DWTXDogwood Therapeutics-$1.22-$0.26+$0.96-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A5.865.86GDTCCytoMed Therapeutics0.065.175.17MGXMetagenomiN/A6.436.43XLOXilio TherapeuticsN/A3.593.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%GDTCCytoMed Therapeutics0.04%MGXMetagenomiN/AXLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics0.30%GDTCCytoMed TherapeuticsN/AMGXMetagenomi12.50%XLOXilio Therapeutics7.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics533.63 million33.53 millionN/AGDTCCytoMed TherapeuticsN/A11.83 millionN/ANot OptionableMGXMetagenomi23637.65 million32.94 millionN/AXLOXilio Therapeutics706.58 million6.09 millionNot OptionableGDTC, DWTX, XLO, and MGX HeadlinesRecent News About These CompaniesXilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% - What's Next?June 9, 2026 | americanbankingnews.comXilio Therapeutics IncJune 2, 2026 | edition.cnn.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesMay 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comXilio Therapeutics Shareholders Approve Flexible Reverse Stock SplitFebruary 24, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGDTC, DWTX, XLO, and MGX Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$1.54 -0.03 (-1.91%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.58 +0.04 (+2.40%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.CytoMed Therapeutics NASDAQ:GDTC$1.14 +0.07 (+6.54%) Closing price 06/12/2026 03:53 PM EasternExtended Trading$1.13 -0.01 (-0.79%) As of 06/12/2026 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Metagenomi NASDAQ:MGX$1.20 -0.05 (-4.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.25%) As of 06/12/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Xilio Therapeutics NASDAQ:XLO$8.31 +0.32 (+4.01%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$8.47 +0.16 (+1.97%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
